Drug Trial Radar · NCT05889273
ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD)
Last checked: Nov 19, 2026Latest source record: Jul 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Jun 1, 2023
Primary completion
Nov 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- MapLight TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jun 5, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 46 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
ML-004-003 is a multi-center, open-label extension study that will enroll approximately 120 adolescent and adult subjects with ASD that have completed study ML-004-002. The primary objective of the study will be to evaluate the safety of ML-004 in subjects with ASD.
Conditions
- Autism Spectrum Disorder
Interventions
ML-004 (IR)/(ER) tabletDrug
Participants will receive ML-004 once daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency of occurrence of treatment-emergent adverse events (TEAEs).Time frame: Baseline up to Day 362
Locations
21 sites in 3 countries. Site status is shown where the registry gives one.
Harmonex Neuroscience Research
Dothan, Alabama
Southwest Autism Research and Resource Center
Phoenix, Arizona
Cortica Healthcare
Glendale, California
NRC Research Institute
Orange, California
Cortica
San Rafael, California
Yale Child Study Center
New Haven, Connecticut
The Children's Research Institute
Washington D.C., District of Columbia
Abba Medical Group
Miami, Florida
APG Research, LLC
Orlando, Florida
University of South Florida Psychiatry and Behavioral Neurosciences
Tampa, Florida
Neurobehavioral Medicine Group
Bloomfield Hills, Michigan
University of Missouri, Thompson Center for Autism & Neurodevelopment
Columbia, Missouri
Nathan Kline Institute for Psychiatric Research
Orangeburg, New York
Richmond Behavioral Associates
Staten Island, New York
Suburban Research Associates
Media, Pennsylvania
BioBehavioral Research of Austin
Austin, Texas
Road Runner Research, Ltd.
San Antonio, Texas
Family Psychiatry of The Woodlands
The Woodlands, Texas
Brain and Mind Centre
Camperdown, New South Wales, Australia
The Royal Children's Hospital, Murdoch Children's Research Institute
Parkville, Victoria, Australia
Holland Bloorview Kids Rehabilitation Hospital
Toronto, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.